| CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions |
43 |
| TIGIT: a novel immunotherapy target moving from bench to bedside |
42 |
| Quantifying tumor-infiltrating immune cells from transcriptomics data |
40 |
| Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer |
33 |
| The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma |
30 |
| Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates |
28 |
| Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody |
28 |
| The binding of an anti-PD-1 antibody to Fc gamma RI has a profound impact on its biological functions |
27 |
| Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders |
25 |
| Opposing roles of eosinophils in cancer |
23 |
| The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy |
22 |
| Targeting myeloid-derived suppressor cells for cancer immunotherapy |
22 |
| Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models |
22 |
| Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies |
20 |
| Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors |
20 |
| Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy |
20 |
| Regulatory mechanisms of PD-L1 expression in cancer cells |
20 |
| Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) |
19 |
| A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression |
19 |
| Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model |
19 |
| Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 |
18 |
| Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells |
18 |
| Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis |
18 |
| Targeting tumor-associated acidity in cancer immunotherapy |
17 |
| Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies |
17 |
| Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia |
17 |
| Indoleamine 3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma |
17 |
| A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer |
17 |
| Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy |
17 |
| Cross-talk between TNF-alpha and IFN-gamma signaling in induction of B7-H1 expression in hepatocellular carcinoma cells |
16 |
| Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report |
16 |
| High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients |
16 |
| Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT |
16 |
| Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer |
16 |
| VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival |
15 |
| T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient |
15 |
| IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients |
15 |
| How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions |
15 |
| Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report |
15 |
| The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer |
15 |
| Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC |
15 |
| Characterization of circulating T NK and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile |
14 |
| Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors |
14 |
| Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein |
14 |
| Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism |
14 |
| First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis |
14 |
| Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter |
13 |
| Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies |
13 |
| mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells |
13 |
| Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation |
13 |
